TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer's Disease (AD)

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Eligible age

50–85 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.

Sponsor: Ludwig-Maximilians - University of Munich

You may qualify if…

  • ✓ Diagnosis of amnestic MCI or AD dementia or clinical normal
  • ✓ Able to provide written informed consent
  • ✓ Unchanged pharmacotherapy within 4 days prior to the study specific assessments
  • ✓ Fluent in German

You may not qualify if…

  • ✕ Unable to give informed consent or has a legal guardian
  • ✕ Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
  • ✕ Clinically relevant depression
  • ✕ Acute suicidality
  • ✕ Current alcohol, drug or medication abuse
  • ✕ History of severe traumatic brain injury within 3 months prior to inclusion
  • ✕ Structural lesions of the basal ganglia or brain stem
  • ✕ Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus

Source: ClinicalTrials.gov · NCT05059158 · last updated 2025-07-04

Amyloid-β Clearance Mechanisms in Alzheimer's Disease · TrialPath